Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2022 third quarter results on August 5, 2022, before market opening. A conference call will follow at 8:00 a.m. ET for analysts and investors to discuss the results and provide business updates. Twist, known for its innovative synthetic DNA manufacturing on silicon chips, continues to expand its offerings, including synthetic genes and tools for next-generation sequencing. Financial results will be posted on their website prior to the call.
Twist Bioscience Corporation (NASDAQ: TWST) has launched synthetic DNA controls for the human monkeypox virus, enhancing its portfolio of next-generation sequencing (NGS) applications for viral diseases. These controls, based on two known clades of the monkeypox virus, will improve the quality and validation of NGS and PCR assays. Twist's synthetic DNA controls cover over 80% of the viral genome and facilitate research and diagnostic tests. The new products align with the company’s commitment to addressing emerging public health concerns.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with DNAnexus to integrate their platforms, enhancing the design, validation, and commercialization of NGS-based diagnostic tests. This partnership enables Twist customers to utilize DNAnexus' cloud-based biomedical data analysis tools alongside Twist’s NGS Methylation Detection and Unique Molecular Identifier Adapter Systems. The collaboration aims to streamline data analysis, ultimately accelerating research in rare diseases and cancer diagnostics.
Twist Bioscience Corporation has announced the opening of its new facility in Quincy, Massachusetts, enhancing its in vivo antibody discovery capacity. This growth aligns with their strategy to accelerate antibody discovery for biopharma partners. The Twist Boston location, previously acquired in November 2021, is equipped with advanced tools, including four Berkeley Lights Beacon® Optofluidic Platforms, aimed at increasing screening capacity. The company plans to further expand its site to support future growth in biologics and diagnostics.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Ildong Pharmaceutical to license a suite of VHH antibody libraries for immuno-oncology applications. The agreement, marking Twist's first collaboration with a South Korean company, includes an upfront payment, annual fees, and royalties on product sales. The VHH libraries, known for their small size and versatility, enable the development of novel therapies targeting various diseases. This partnership aims to enhance Ildong's pipeline and supports Twist's strategic expansion in the Asia-Pacific region.
Twist Bioscience Corporation (NASDAQ: TWST) announced that Steffen Hellmold, Senior VP of Business Development for Data Storage, will present at the Fujifilm 12th Annual Global IT Executive Summit in San Diego, CA, from June 22-25, 2022. Hellmold's presentation, titled "Scaling up from Data Lakes to Data Oceans," is scheduled for June 23, 3:15-3:45 PM PT. The summit focuses on data management trends and how DNA data storage can address exponential data growth. Twist Bioscience leverages a proprietary DNA synthesis platform for various applications across industries, including healthcare and agriculture.
Twist Bioscience has launched the Twist MRD Rapid 500 Panel, priced at
This innovative solution targets up to 500 genomic regions and allows researchers to receive tailored panels in as little as five days, significantly improving the monitoring of cancer treatment responses.
The product integrates with standard NGS workflows, potentially enhancing sequencing sensitivity while aiding in disease surveillance.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust, Ph.D., and CFO Jim Thorburn will present at two upcoming investor conferences. They will speak at the William Blair Growth Stock Conference on June 9 at 1:20 p.m. CT in Chicago, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14 at 10:40 a.m. PT in Rancho Palos Verdes. Both presentations will be webcast live and available for replay on the company's investor relations website for 30 days.
Twist Bioscience Corporation (NASDAQ: TWST) has launched the Twist Human Methylome Panel, designed to enhance research in cancer metastasis and human development. This innovative panel covers 84.2% of CpG islands and offers significant cost savings compared to traditional methods. The panel allows researchers to identify biologically relevant methylation markers, thereby supporting advanced applications in liquid biopsy technologies. It promises a higher dynamic range for accurate detection of differentially methylated regions, facilitating better diagnostic tests and research assays.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust and CFO Jim Thorburn will participate in a fireside chat at the 2022 UBS Global Healthcare Conference on May 23 at 9:15 a.m. ET in New York. The event will be webcast live, accessible via the company’s Investor Calendar. A replay will be available for 30 days after the live event. Twist Bioscience is a leader in synthetic biology, utilizing innovative DNA synthesis technology to produce synthetic DNA for various applications, including healthcare and drug discovery.